Fenwick partners: IPO rebound shifts biotech risk

Biotech IPO demand has surged this year, but the market remains selective, Fenwick partners Amanda Rose and Chelsea Anderson tell Axios Pro.

The big picture: The IPO rebound is shifting the market's read on biotech risk, while clinical-trial betting is opening a new front around disclosure.

Catch up quick: Fenwick represented Attovia Therapeutics in its $289 million IPO, and also advised Scribe on its public offering in July.

• Rose is co-lead of the firm's capital markets practice and Anderson is a corporate partner.